Correspondence n engl j med 375;8 nejm.org August 25, 2016 803 less likely to have a response to the drug or survive to hospital discharge. We agree that earlier use of antiarrhythmic drugs provides a greater potential for clinical benefit that may be lost if the drugs are administered late. For example, in prespecified subgroup analyses in our trial, we observed no effect (neither benefit nor harm) from active drug among 839 patients with unwitnessed out-of-hospital cardiac arrest; these patients typically have a more prolonged duration between arrest and treatment than do patients with witnessed out-of-hospital arrest. Conversely, among 1934 patients with out-of-hospital cardiac arrest that was witnessed by a bystander, the rate of survival to hospital discharge was significantly increased by an absolute margin of 5 percentage points with active drug as compared with placebo (P≤0.04). Furthermore, among 154 patients in whom out-of-hospital cardiac arrest was witnessed by EMS and cardiopulmonary resuscitation, shock, and the study drug were administered soon after the arrest, the absolute increase in survival to hospital discharge with amiodarone as compared with placebo was 21.9 percentage points (P<0.01). These findings suggest a pronounced drug effect in patients who are in an earlier, more responsive stage of cardiac arrest. The overall results of the trial are arguably best interpreted in the context of this group of patients.
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To the Editor: Welch and Robertson suggest that screening cannot explain the entire decline in colorectal-cancer incidence and mortality (i.e., overall decreases of 40% and 50%, respectively, among adults in the United States) in the period from 1975 to 2012 and that other factors (e.g., risk factors such as diet, lifestyle, and drugs) must be involved. Surprisingly, the authors did not cite the respective proportions of the decline that were attributable to screening as opposed to those other factors, as analyzed in the "Annual Report to the Nation on the Status of Cancer, 1975 Cancer, -2006 ," which features colorectal-cancer trends and the effect of risk factors, screening, and treatment. 1 Using the well-validated Microsimulation Screening Analysis (MISCAN)-Colon model, 2 the authors of that report concluded that 53% of the overall observed decline in colorectalcancer-related mortality could be explained by screening, as compared with 35% that could be explained by changes in risk factors and 12% by treatment. 1 The same MISCAN-Colon model allowed analysts to suggest that differences in screening accounted for 42% and 19% of the observed disparities in colorectal-cancer incidence and mortality, respectively, between blacks and whites in the United States.
